Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
Verlagsversion
DOI
PMC
 |
Open Access Gold |
|
möglich sobald bei der ZB eingereicht worden ist.
Changes in metabolomic profiles induced by switching from an erythropoiesis-stimulating agent to a hypoxia-inducible factor prolyl hydroxylase inhibitor in hemodialysis patients: A pilot study.
Int. J. Mol. Sci. 24:14 (2023)
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of medications for managing renal anemia in patients with chronic kidney disease (CKD). In addition to their erythropoietic activity, HIF-PHIs exhibit multifaceted effects on iron and glucose metabolism, mitochondrial metabolism, and angiogenesis through the regulation of a wide range of HIF-responsive gene expressions. However, the systemic biological effects of HIF-PHIs in CKD patients have not been fully explored. In this prospective, single-center study, we comprehensively investigated changes in plasma metabolomic profiles following the switch from an erythropoiesis-stimulating agent (ESA) to an HIF-PHI, daprodustat, in 10 maintenance hemodialysis patients. Plasma metabolites were measured before and three months after the switch from an ESA to an HIF-PHI. Among 106 individual markers detected in plasma, significant changes were found in four compounds (erythrulose, n-butyrylglycine, threonine, and leucine), and notable but non-significant changes were found in another five compounds (inositol, phosphoric acid, lyxose, arabinose, and hydroxylamine). Pathway analysis indicated decreased levels of plasma metabolites, particularly those involved in phosphatidylinositol signaling, ascorbate and aldarate metabolism, and inositol phosphate metabolism. Our results provide detailed insights into the systemic biological effects of HIF-PHIs in hemodialysis patients and are expected to contribute to an evaluation of the potential side effects that may result from long-term use of this class of drugs.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Clinical Trial ; Erythropoiesis-stimulating Agents ; Hemodialysis ; Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors ; Metabolomic Analysis ; Pleiotropic Effects; Chronic Kidney-disease; Insulin-resistance; Darbepoetin Alpha; Double-blind; Anemia; Phase-3; Myoinositol; Roxadustat; Vadadustat; Efficacy
ISSN (print) / ISBN
1422-0067
e-ISSN
1661-6596
Zeitschrift
International Journal of Molecular Sciences
Quellenangaben
Band: 24,
Heft: 16,
Artikelnummer: 14
Verlag
MDPI
Verlagsort
Basel
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Metabolism and Cell Death (MCD)
Förderungen
JSPS KAKENHI
This work was supported by JSPS KAKENHI Grant Number 22K11347.
JSPS KAKENHI
This work was supported by JSPS KAKENHI Grant Number 22K11347.